--- title: Buy Natdac (Tenofovir/Daclatasvir/Sofosbuvir) 60mg Pills Online description: Natdac with Tenofovir disoproxil, Daclatasvir, and Sofosbuvir treats chronic hepatitis C. Secure online ordering with verified quality assured. type: product language: en url: https://medsforsale.net/buy-natdac-online-en availability: in_stock price_min: 274.99 price_max: 412.99 currency: USD offers: - name: 60mg x 28 pills price: 274.99 - name: 60mg x 56 pills price: 412.99 --- # Buy Natdac (Tenofovir/Daclatasvir/Sofosbuvir) 60mg Pills Online Natdac includes Tenofovir disoproxil, Daclatasvir, and Sofosbuvir in pill strength. This antiviral combination targets hepatitis C virus replication for treatment of chronic HCV infection. Intended for adults undergoing HCV therapy. Order Natdac 60mg pills from our dependable online pharmacy. ## Pricing and Options | Dosage | Pack Size | Price (USD) | Price Per Pill | Status | | :--- | :--- | :--- | :--- | :--- | | **60mg** | 28 pills | **$274.99** | $9.82 | In Stock | | **60mg** | 56 pills | **$412.99** | $7.37 | In Stock | [Buy Now](https://medsforsale.net/buy-natdac-online-en) ## Introduction Natdac is a fixed-dose oral tablet that contains three antiviral agents: tenofovir disoproxil, daclatasvir, and sofosbuvir. The medication is supplied as a 60 mg pill and is intended for adult patients who require antiviral therapy for chronic viral infections, particularly hepatitis C virus (HCV) and hepatitis B virus (HBV) co-infection. While tenofovir disoproxil is approved for HBV and HIV, the combination of daclatasvir and sofosbuvir is an established regimen for HCV genotypes 1-4. Natdac brings these agents together in a single tablet, simplifying dosing for patients who may need both HBV and HCV treatment. The product is manufactured by an international pharmaceutical company that follows Good Manufacturing Practice (GMP) standards. Off-label use of Natdac has been reported in clinical investigations of HBV/HCV co-infection, but such use remains experimental and is not endorsed by regulatory authorities. ## What is Natdac? Natdac is the generic version of well-known medications containing the active compounds tenofovir disoproxil, daclatasvir, and sofosbuvir. [our online pharmacy](https://medsforsale.net/buy-natdac-online-en) provides this generic alternative as a cost-effective treatment option. The tablet belongs to the antiviral drug class and is formulated to deliver a fixed amount of each component in a single oral dose. The product is manufactured by a licensed supplier that adheres to international quality-control guidelines. ## How Natdac Works * **Tenofovir disoproxil** is a prodrug that is converted in the body to tenofovir diphosphate. This metabolite competitively inhibits the reverse transcriptase enzyme of HBV, preventing synthesis of viral DNA and thereby reducing viral replication. * **Daclatasvir** binds to the non-structural protein 5A (NS5A) of HCV. NS5A is essential for viral RNA replication and assembly of new virus particles. By inhibiting NS5A, daclatasvir blocks the production of infectious HCV virions. * **Sofosbuvir** is a nucleoside analogue that is phosphorylated intracellularly to the active triphosphate form. This active metabolite targets the HCV NS5B RNA-dependent RNA polymerase, causing chain termination during viral RNA synthesis. When combined, tenofovir addresses HBV replication while daclatasvir and sofosbuvir provide a synergistic, pan-genotypic attack on HCV. The triple regimen therefore aims to suppress both viruses simultaneously, which can be advantageous in patients infected with both HBV and HCV. The onset of antiviral activity for the HCV components is typically observed within a few days, with maximal viral suppression achieved after several weeks of continuous therapy. Tenofovir has a longer intracellular half-life, allowing sustained HBV inhibition throughout treatment. ## Conditions Treated with Natdac * **Chronic hepatitis C infection (genotypes 1-4).** The daclatasvir-sofosbuvir combination is approved in many jurisdictions for HCV treatment, achieving sustained virologic response rates exceeding 95 % in clinical trials. * **Chronic hepatitis B infection (as part of combination therapy).** Tenofovir disoproxil is an FDA- and EMA-approved therapy for HBV, reducing viral load and preventing disease progression. Natdac is not presently approved by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), or other major regulatory bodies as a single fixed-dose product. Its use therefore relies on the individual approvals of its constituents. In clinical practice, physicians may prescribe the three agents separately; Natdac offers a consolidated tablet for patients who meet specific therapeutic goals under specialist supervision. ## Off-Label and Investigational Uses of Natdac * **HBV/HCV co-infection.** Small phase II studies have evaluated the triple combination in patients with simultaneous HBV and HCV infection. Preliminary data suggest that concurrent suppression of both viruses is feasible, but the safety profile requires further confirmation. * **Pre-exposure prophylaxis (PrEP) for HIV in patients with chronic HCV.** Tenofovir disoproxil is a cornerstone of HIV PrEP. Some clinicians have considered adding daclatasvir and sofosbuvir to address co-existing HCV, though no formal guidelines endorse this approach. * **Compensated cirrhosis due to HCV with underlying HBV.** In patients with advanced liver disease, early viral eradication of HCV may improve liver function, while tenofovir protects against HBV reactivation. Case series have reported successful outcomes, yet controlled trials are lacking. These applications remain investigational. Regulatory agencies have not approved Natdac for any of the above uses. Patients should not pursue off-label treatment without direct oversight by a qualified healthcare professional. ## Is Natdac the Right Medication for You? Natdac may be appropriate for adult patients who: * Have documented chronic HCV infection (genotype 1-4) requiring an all-oral, pan-genotypic regimen. * Have chronic HBV infection that is well-controlled with tenofovir, but would benefit from simultaneous HCV therapy. * Are able to adhere to a once-daily dosing schedule and have no contraindicating conditions. Contraindications include: * Known hypersensitivity to tenofovir, daclatasvir, sofosbuvir, or any excipients in the tablet. * Severe renal impairment (creatinine clearance < 30 mL/min) without dose adjustment, as tenofovir accumulation can cause nephrotoxicity. * Pregnancy or breastfeeding unless the benefits clearly outweigh potential risks; tenofovir is category B, while daclatasvir and sofosbuvir are category B in animal studies but lack extensive human data. Patients with decompensated liver disease, uncontrolled HIV infection, or active opportunistic infections should be evaluated carefully before initiating Natdac. ## Risks, Side Effects, and Interactions ### Common - Fatigue or mild weakness - Headache - Nausea or mild gastrointestinal upset - Insomnia ### Rare - Elevated liver enzymes (ALT/AST) indicating hepatic irritation - Decrease in bone mineral density (associated with tenofovir) - Peripheral neuropathy ### Serious - Acute kidney injury or worsening chronic kidney disease (tenofovir) - Severe hypersensitivity reactions, including Stevens-Johnson syndrome or drug rash with eosinophilia and systemic symptoms (DRESS) - Hepatic decompensation in patients with advanced cirrhosis #### Drug-Drug Interactions - **Coadministration with strong CYP3A4 inducers** (e.g., rifampicin, carbamazepine) can lower daclatasvir concentrations, reducing antiviral efficacy. - **Proton pump inhibitors (PPIs)** may modestly decrease daclatasvir absorption; stagger dosing or use H₂ antagonists if necessary. - **Nephrotoxic agents** (e.g., aminoglycosides, non-steroidal anti-inflammatory drugs) should be avoided or monitored closely when using tenofovir. - **Anticoagulants** such as warfarin may exhibit altered INR values; regular monitoring is advised. Patients should disclose all prescribed, over-the-counter, and herbal products before starting Natdac. ## Use: Dosing, Missed Dose, Overdose **Standard dosing** for Natdac in adults is one 60 mg tablet taken orally once daily with food to improve absorption of the HCV components. The duration of therapy is typically 12 weeks for HCV genotype 1-4, but may extend to 24 weeks in patients with cirrhosis or prior treatment failure, following specialist recommendation. **Missed dose:** If a dose is forgotten within 12 hours of the scheduled time, take it as soon as remembered. If more than 12 hours have elapsed, skip the missed dose and resume the regular dosing schedule. Do not double-dose. **Overdose:** Signs of overdose may include severe nausea, vomiting, dizziness, or acute renal dysfunction. Seek immediate medical attention; supportive care, including hydration and monitoring of renal function, is the mainstay of treatment. **Practical precautions:** - Take the tablet with a full glass of water and a meal; high-fat meals do not significantly affect absorption. - Avoid excessive alcohol, as it can exacerbate liver injury. - Do not operate heavy machinery or drive until you know how Natdac affects you, especially during the first few days of therapy. ## FAQ - **Can I travel internationally with Natdac?** Natdac can be carried in its original packaging with a copy of the prescription (if required by the destination country). Some nations have strict import rules for antiviral medications; verify local regulations before departure. - **What does the Natcad tablet look like?** The 60 mg tablet is round, bicolored (typically white with a blue imprint), and scored for easy splitting if a dose adjustment is ever needed under medical guidance. - **Are there any sugar or gluten ingredients in Natdac?** Inactive ingredients commonly include microcrystalline cellulose, magnesium stearate, and lactose. Patients with severe lactose intolerance should discuss alternatives with their provider. - **How should Natdac be stored in hot climates?** Store the tablet at controlled room temperature (15-30 °C). In environments exceeding 30 °C, keep the medication in a cool, dry place, such as an insulated container, to preserve stability. - **Will Natdac show up on a standard drug test?** Routine employment drug screens do not test for antiviral agents. However, specialized testing can detect tenofovir, daclatasvir, or sofosbuvir if specifically requested. - **Is Natdac safe for patients with a history of kidney stones?** Tenofovir may increase the risk of renal tubular dysfunction, which could aggravate stone formation. Regular renal monitoring is recommended for patients with prior kidney issues. - **Do I need to adjust Natdac before a surgical procedure?** Generally, continue Natdac up to the day of surgery unless the anesthesiologist advises otherwise. Discuss peri-operative management with your surgical team, especially if renal function is a concern. - **What are the key differences between Natdac and separate tablets of tenofovir, daclatasvir, and sofosbuvir?** Natdac consolidates three agents into a single pill, reducing pill burden and simplifying adherence. Pharmacokinetic profiles remain comparable to the individual drugs when taken at equivalent doses. - **Can Natdac be used in patients with a BMI over 35 kg/m²?** No dosage adjustment is required based solely on body mass index, but clinicians may monitor drug levels and liver function more closely in obese patients due to altered pharmacodynamics. - **Is there a known interaction between Natdac and herbal supplements such as St. John’s Wort?** St. John’s Wort induces CYP3A4 and can lower daclatasvir concentrations, potentially compromising HCV treatment efficacy. Patients should avoid this supplement while on Natdac. ## Glossary **Reverse transcriptase inhibitor** : A class of drugs that block the enzyme reverse transcriptase, preventing viruses like HBV or HIV from copying their genetic material. **NS5A inhibitor** : A medication that interferes with the non-structural protein 5A of HCV, disrupting viral replication and assembly. **Sustained virologic response (SVR)** : The absence of detectable virus in the blood 12 weeks after completing antiviral therapy, considered a cure for HCV. ## Buying Natdac from [our online pharmacy](https://medsforsale.net/buy-natdac-online-en) Natdac can be obtained through [our online pharmacy](https://medsforsale.net/buy-natdac-online-en), which specializes in providing certified generic medications at prices close to the manufacturer’s cost. We source every batch from licensed, GMP-compliant suppliers, ensuring that the product meets stringent quality standards. Delivery is discreet, with plain-packaging options and reliable shipping timelines-typically 7 days for express service and approximately 3 weeks for standard airmail. Our pharmacy broker model connects patients directly with overseas licensed pharmacies, expanding access to treatments that may be scarce or unaffordable through conventional channels. Privacy is a core principle; personal data is encrypted, and all shipments are packaged to protect confidentiality. By choosing our service, patients gain a secure, affordable pathway to obtain Natdac without compromising on safety or discretion. ## Disclaimer The information presented about Natdac is intended for general educational purposes and does not substitute for professional medical advice. Treatment decisions, including any off-label use, must be made under the direct supervision of a qualified healthcare provider. Readers are assumed to be competent adults capable of making informed health choices. [our online pharmacy](https://medsforsale.net/buy-natdac-online-en) supplies Natdac for individuals who encounter limited availability through traditional pharmacies or who seek cost-effective generic alternatives. Always consult a healthcare professional before initiating, modifying, or stopping any medication.